当前位置： SCI文献检索 > EPILEPSY RESEARCH期刊下所有文献 > Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome.

Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome.

Abstract：

OBJECTIVE:To describe the use of a population pharmacokinetic (PopPK) model incorporating weight and ontogeny to identify effective clobazam (CLB) dosing for use in a clinical trial in pediatric patients with Dravet syndrome. METHODS:Pharmacokinetic data were combined from 3 CLB trials (OV-1012, OV-1017, and study 301) and a simulated study (study 401) for a total of 1306 CLB and 1305 N-desmethyl clobazam (N-CLB) samples from 193 Lennox-Gastaut syndrome patients and healthy subjects aged 6 months to 45 years. A structured approach based on US Food and Drug Administration guidance and pharmacometric knowledge discovery was developed using a nonlinear mixed-effects approach. Graphing and fitting using logistical weight regression were used to identify covariates for inclusion in the final model, which was evaluated using goodness-of-fit criteria and validated using prediction-corrected visual predictive check (pcVPC). Using the final PopPK model, a simulation study determined CLB and N-CLB distributions after 4 weeks of 1.5 and 2.0 mg/kg CLB. RESULTS:The parameters of the final PopPK model were similar to previous reports. Fixed-effect parameters were precisely estimated, with no significant increase in NONMEM objective function value. Intersubject variability estimates were similar to previous reports, with <35% shrinkage associated with parameter variability, except for intercompartmental clearance and apparent volumes of distribution of peripheral compartments. Goodness-of-fit plots and pcVPC show that the model adequately described CLB and N-CLB data. The CLB/N-CLB ratio in virtual study subjects aged <3 years was 0.23 for 1.5 and 2.0 mg/kg and was 0.14 for subjects aged ≥3 years, which is 2 to 3 times those reported in a previous stiripentol/CLB/valproate study in which seizure improvement was reported. SIGNIFICANCE:The PopPK model dosing parameters of 1.5 and 2.0 mg/kg are likely to result in efficacious concentrations of CLB and N-CLB in pediatric patients as young as 16 months. Dosages exceeding 1.5 mg/kg should be monitored for tolerability, particularly in patients aged <2 years, as there may be a higher incidence of sedation.

journal_name

Epilepsy Res

journal_title

Epilepsy research

authors

Tolbert D,Chu HM,Ette EI

doi

10.1016/j.eplepsyres.2019.106182

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

106182

eissn

0920-1211

issn

1872-6844

pii

S0920-1211(19)30175-5

journal_volume

157

pub_type

杂志文章

在线工具

Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome.